{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:56:58Z","timestamp":1792785418314,"version":"4.5.0"},"reference-count":160,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"the Key Research & Development project of Science Technology Department of Zhejiang Province","award":["2024C03057"],"award-info":[{"award-number":["2024C03057"]}],"id":[{"id":"https:\/\/ror.org\/05yj3y977","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines","award":["2025ZY01051"],"award-info":[{"award-number":["2025ZY01051"]}]},{"name":"Postdoctoral Research Startup Funds of Hangzhou Normal University","award":["4275C5022621508, 4275C5022621510"],"award-info":[{"award-number":["4275C5022621508, 4275C5022621510"]}],"id":[{"id":"https:\/\/ror.org\/014v1mr15","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/13543776.2026.2713551","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T01:29:38Z","timestamp":1785979778000},"page":"911-936","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["An updated patent review of STAT6 inhibitors and modulators (2020 \u2013 present)"],"prefix":"10.1080","volume":"36","author":[{"given":"Muhammad Zafar Irshad","family":"Khan","sequence":"first","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Qun","family":"Du","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Ran","family":"Li","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshe","family":"Wang","sequence":"additional","affiliation":[{"name":"Hangzhou Purple Crystal Pharma","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9276-9555","authenticated-orcid":false,"given":"Chen-Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]},{"name":"Hangzhou Normal University","place":["Hangzhou, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3264"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0445-6"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.293"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239004"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122002"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12164"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.2.351"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.104"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1333"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8085155"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694370"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2006.01.004"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153477"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1998.5436"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.28.17634"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050117"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203485"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8205-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.6.3336"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.023"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R700016200"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-871293"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.3c00926"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6382"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00078"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.701"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/2.7.669"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(02)00318-X"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-019-0189-6"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-012-2063-0"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2001.02417.x"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.05.009"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0412214"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/380630a0"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80439-2"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.1.39"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(00)00082-1"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.9.4350"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep30977"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M910290199"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011475200"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.10.5045"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2778"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.36.22175"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.09.008"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-1492fje"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0631"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.10.5590"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.13.6231"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.10.5811"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221755"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.023"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001439"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-582650"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0428-0"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.85"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3545"},{"key":"e_1_3_4_62_1","unstructured":"Bacus SS. Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer. U.S. Patent application. Gopath Laboratories LLC 2023;18\/014 053."},{"key":"e_1_3_4_63_1","unstructured":"Auransa INC. Palo Alto CA (US). Methods for treating a subtype of small cell lung cancer. US20210378992A1. 2021."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001027"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2020.03.007"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-01968-3"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2522"},{"key":"e_1_3_4_68_1","unstructured":"FIGENE LLC Houston TX (US). Immunotherapeutic methods and compositions for targeting cancer fibroblasts. US20230149466A1. 2023."},{"key":"e_1_3_4_69_1","unstructured":"Nanjing Legend Biotech Co. Ltd. Nanjing (CN). Genetic engineering of gamma delta t cells for immunotherapy. US20230226181A1. 2023."},{"key":"e_1_3_4_70_1","unstructured":"The U.S. of America as represented by the Secretary Department of Health and Human Services [US]. Methods of treating diffusal large B cell lymphoma based on particular genetic subtype. WO2021173796A1. 2021."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4266-0"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.11.043"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2020-0125"},{"key":"e_1_3_4_74_1","unstructured":"University of Florida Research Foundation INC. Gainesville FL (US). Slow-cycling cell-RNA based nanoparticle vaccine to treat cancer. US20220054610A1. 2022."},{"key":"e_1_3_4_75_1","unstructured":"University of Florida Research Foundation INC. Gainesville FL (US). Immunotherapy for direct reprogramming of cancer cells into immune cells\/antigen presenting cells\/dendritic cells. US20230046425A1. 2023."},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2016.16.4.201"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0119-7"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00186.2019"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615868"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.97"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1031"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.398"},{"key":"e_1_3_4_83_1","unstructured":"Pacific Myco Biosciences Ltd. Kelowna (CA). A method of immune modulation by modulating ABCF1. US20220125876A1. 2022."},{"key":"e_1_3_4_84_1","unstructured":"KAO CORPORATION Chuo-ku Tokyo (JP); Juntendo educational Foundation bunkyo-Ku Tokyo (JP). Method for detecting parkinson\u2019s disease. US20230183806A1. 2023."},{"key":"e_1_3_4_85_1","unstructured":"University of Virginia patent Foundation Charlottesville VA (US). Jonathan Kipnis Charlottesville VA (US); Sandro Da Mesquita Charlottesville VA (US). Compositions and methods of diagnosis and treatment for neurological diseases. US20210311076A1. 2021."},{"key":"e_1_3_4_86_1","unstructured":"Larsen JCH Larsen M Ritzen A. Leo Pharma AS. Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof. WO 2020\/007698 A1. 2020."},{"key":"e_1_3_4_87_1","unstructured":"LEO Pharma A\/S. Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof. EP 3818060 B1. 2023."},{"key":"e_1_3_4_88_1","unstructured":"Theravance Biopharma R&D IP LLC [US\/US]; 901 gateway blvd South San Francisco California 94080 (US). Method of treating a patient infected with a coronavirus with nezulcitinib. WO2021226637A1. 2021."},{"key":"e_1_3_4_89_1","unstructured":"Chiesi Farmaceutici S.P.A (IT); Via Palermo 26\/A. 431222 Parma (IT). Heterocyclic derivatives as jenus kinase inhibitors. WO2024052512A1. 2024."},{"key":"e_1_3_4_90_1","unstructured":"The Catholic University of Korea Industry-Academic Cooperation Foundation (KR); Gachon University of Industry -Academic Cooperation Foundation (KR). Treat composition inhibiting systemic scler vimentin mutant protein activity using STAT6 inhibitor. WO2024107017A1. 2024."},{"key":"e_1_3_4_91_1","unstructured":"Colson PJ Fass GT. Theravance Biopharma R&D IP LLC. Process for preparing JAK inhibitors and intermediates thereof. U.S. Patent 10 844 057. 2020."},{"key":"e_1_3_4_92_1","unstructured":"McKinnell RM Lam TM Smith C et al. Theravance Biopharma R&D IP LLC 2025. Imidazolo indazole compounds as JAK inhibitors. U.S. Patent 12 384 761."},{"key":"e_1_3_4_93_1","unstructured":"Theravance Biopharma R&D IP LLC 2020. Bicyclic inhibitors of JAK and methods of use. WO2023091707A1. 2023."},{"key":"e_1_3_4_94_1","unstructured":"Theravance Biopharma R&D IP LLC 2020. Amino amide tetrahydro Imidazo pyridines as JAK inhibitors. WO2022178215A1. 2022."},{"key":"e_1_3_4_95_1","unstructured":"Vegas AJ Quinnell SP Sheehy DF et al. Boston University. Small molecule inhibitors of interleukin-4 and uses thereof. U.S. Patent application 19\/171 111. 2025."},{"key":"e_1_3_4_96_1","unstructured":"Gilead Sciences INC. California (US). Small molecules modulators of STAT6. WO2025207818A1. 2025."},{"key":"e_1_3_4_97_1","unstructured":"Almirall S.A. Barcelona (ES). STAT6 inhibitors and methods of use thereof. WO2025172431A1. 2025."},{"key":"e_1_3_4_98_1","unstructured":"Pfizer INC. New York 10001\u20132192 (US). Nitrogen-containing heteroaryl compounds for the treatment of chronic diseases. WO2025133961A1. 2024."},{"key":"e_1_3_4_99_1","unstructured":"NBIOS INC. 25457 gangwon-do (KR). Phlebiarubrone derivative and composition for preventing alleviating or treating inflammatory diseases comprising same as active ingredient. WO2025018447A1. 2025."},{"key":"e_1_3_4_100_1","unstructured":"Long DD Smith C Thompson C. Theravance Biopharma R&D IP LLC. 5 to 7 membered heterocyclic amides as JAK inhibitors. U.S. Patent 10 836 763. 2020."},{"key":"e_1_3_4_101_1","unstructured":"Kymera Therapeutics INC. Watertown MA (US). STAT6 inhibitors and uses thereof. US20250213586A1. 2025."},{"key":"e_1_3_4_102_1","unstructured":"Dizal (Jiangsu) pharmaceutical Co. LTD. (CN). JAK1 selective kinase inhibitor. WO2020211839A1. 2020."},{"key":"e_1_3_4_103_1","unstructured":"Long DD Smith C Thompson C. Theravance Biopharma R&D IP LLC. Dimethyl amino azetidine amides as JAK inhibitors. U.S. Patent 10 947 229. 2021."},{"key":"e_1_3_4_104_1","unstructured":"Crater GD Moran EJ Saggar R et al. Theravance Biopharma R&D IP LLC. Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compound. U.S. Patent application 17\/302 594. 2025."},{"key":"e_1_3_4_105_1","unstructured":"Bifulco N Bregman H Cianchetta G et al. Recludix Pharma INC. Cambridge MA (US). 6-oxodecahydropyrrolo [1 2-a][1 5] diazocine and 6-oxodecahydro-4h-pyrrolo [2 1-d][1 5] thiazocine derivatives as stat3 and stat6 modulators for the treatment of cancer and inflammatory conditions. U.S. Patent application 202501179103A1. 2025."},{"key":"e_1_3_4_106_1","unstructured":"Bregman H Bifulco N Cianchetta G et al. Recludix Pharma INC. Cambridge MA (US). STAT6 modulators and uses thereof. US20250215029A1. 2025"},{"key":"e_1_3_4_107_1","unstructured":"Board regents Univ Tex system Austin TX (US). Methods producing Regul b cells uses thereof. US20220175837A1. 2020."},{"key":"e_1_3_4_108_1","unstructured":"Regents of the University of Michigan ann Arbor MI (US). STAT5 and STAT6 degraders and uses thereof. US20230295197A1. 2023."},{"key":"e_1_3_4_109_1","unstructured":"Regents of the University of Michigan ann Arbor MI (US). STAT5 and STAT6 degraders and uses thereof. US20230295200A1. 2023."},{"key":"e_1_3_4_110_1","unstructured":"Bin Y Bruce C Huijin D et al. Kymera Therapeutics INC. Watertown MA (US). STAT6 degraders and uses thereof. WO2024064080A1. 2024"},{"key":"e_1_3_4_111_1","unstructured":"Bin Y Bruce C Huijin D et al. Kymera Therapeutics INC. Watertown MA (US). annotation STAT6 degraders and uses thereof. PCT\/US\/2024\/044544. 2024"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.25251\/t4cqj323"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3443"},{"key":"e_1_3_4_114_1","unstructured":"Pfizer. A phase 2b randomized double-blind placebo-controlled dose-ranging study to evaluate the efficacy and safety of PF-08049820 in adult participants with moderate to severe atopic dermatitis. ClinicalTrials.Gov identifier: NCT07216027. 2025."},{"key":"e_1_3_4_115_1","unstructured":"Gilead Sciences INC. California (US). STAT6 degraders. WO2025207825A1. 2025."},{"key":"e_1_3_4_116_1","unstructured":"Gilead Sciences INC. California (US). STAT6 degraders. WO2025207822A1. 2025."},{"key":"e_1_3_4_117_1","unstructured":"Gilead Sciences INC. California (US). Small molecule modulators of STAT6. WO2025207819A1. 2025."},{"key":"e_1_3_4_118_1","unstructured":"Inventisbio Co. LTD. Shanghai (CN) Inventisbio LLC New Jersey (US). Compounds preparation methods and uses thereof. WO2025103477A1. 2025."},{"key":"e_1_3_4_119_1","unstructured":"The Cleveland clinic Foundation Cleveland OH (US). BACE1 inhibition for the treatment of cancer. US20210069205A1. 2021."},{"key":"e_1_3_4_120_1","unstructured":"Astrazeneca AB; Sodertalje (SE). Lipocalin Mutein for treatment of asthma. WO2020200960A1. 2020."},{"key":"e_1_3_4_121_1","unstructured":"Qyuns Therapeutics Co. Ltd. Taizhou Jiangsu (CN). Monoclonal antibody against human interleukin-4 receptor alpha and use thereof. EP3902837B1. 2025."},{"key":"e_1_3_4_122_1","unstructured":"Qyuns Therapeutics Co. Ltd. Taizhou Jiangsu (CN). Monoclonal antibody against human interleukin-4 receptor alpha and use thereof. US20220073631A1. 2022."},{"key":"e_1_3_4_123_1","unstructured":"Qyuns Therapeutics Co. Ltd. Taizhou Jiangsu (CN). Monoclonal antibody against human interleukin-4 receptor alpha and use thereof. WO2020135471A1. 2020."},{"key":"e_1_3_4_124_1","unstructured":"Qyuns Therapeutics Co. Ltd. Taizhou Jiangsu (CN). Monoclonal antibodies against human interleukin-4 receptor alpha encoding nucleic acids thereof and method of use thereof to treat il-4 or il-4\/il-13-mediated diseases. US12297280B2. 2025."},{"key":"e_1_3_4_125_1","unstructured":"Chia Tai Tianqing pharmaceutical group Co. Ltd. Lianyungang Jiangsu 222062 (CN). Pharmaceutical composition of anti-IL4R antibody and use thereof. EP4393506A1. 2023."},{"key":"e_1_3_4_126_1","unstructured":"Chia Tai Tianqing pharmaceutical group Co. Ltd. Lianyungang Jiangsu 222062 (CN). Pharmaceutical composition of anti-IL4R antibody and use thereof. (WO2023025217A1). 2023."},{"key":"e_1_3_4_127_1","unstructured":"Chia Tai Tianqing pharmaceutical group Co. Ltd. Lianyungang Jiangsu 222062 (CN). Pharmaceutical composition of anti-IL4R antibody and use thereof. US20240343815A1. 2024."},{"key":"e_1_3_4_128_1","unstructured":"Chia Tai Tianqing pharmaceutical group Co. Ltd. Lianyungang Jiangsu 222062 (CN). Antibodies binding IL4R and uses thereof. WO2021170020A1. 2021."},{"key":"e_1_3_4_129_1","unstructured":"Akeso Biopharma INC. Zhongshan Guangdong 528437 (CN). Anti-human IL4RA antibody and application thereof. EP4516315A1. 2023."},{"key":"e_1_3_4_130_1","unstructured":"Akeso Biopharma INC. Zhongshan Guangdong 528437 (CN). Anti-human IL4RA antibody and application thereof. US20250304703A1. 2024."},{"key":"e_1_3_4_131_1","unstructured":"Biosion INC. Nanjing Jiangsu (CN). Recombinant bispecific antibodies targeting TSLP and IL4R. WO2024061279A1. 2024."},{"key":"e_1_3_4_132_1","unstructured":"Interk Peptide Therapeutics LTD (AU). Compositions methods treat autoimmunity incl autoimmunity associated cancer cancer ther. WO2023019323A1. 2023."},{"key":"e_1_3_4_133_1","unstructured":"The J. David Gladstone Institutes a testamentary trust established under the will of J. David Glads San Francisco CA (US); Regents of the University of California Oakland CA (US). Retroelement-generated transcription factor decoys. US20250011787A1. 2025."},{"key":"e_1_3_4_134_1","unstructured":"Invetx INC. Boston MA (US). Anti-IL-4RA antibodies and uses thereof. US20250188176A1. 2024."},{"key":"e_1_3_4_135_1","unstructured":"Intervet International B.V. Boxmeer (NL). Canine interleukin-4 Recept alpha Antibodies. WO2021123091A1. 2021."},{"key":"e_1_3_4_136_1","unstructured":"Eli Lilly and company Indiana (US). Human interleukin-4 receptor alpha antibodies. WO2023015278A1. 2023."},{"key":"e_1_3_4_137_1","unstructured":"Aslan Pharmaceuticals Pte Ltd Singapore (SG). Method for treatment of moderate to severe atopic dermatitis. WO2023048651A1. 2022."},{"key":"e_1_3_4_138_1","unstructured":"Aslan Pharmaceuticals Pte Ltd Singapore (SG). Method for treatment of moderate to severe atopic dermatitis. US20250002592A1. 2024."},{"key":"e_1_3_4_139_1","unstructured":"Kindred Biosciences INC. California (US). Anti-IL4 receptor antibodies for veterinary use. WO2020056393A1. 2020."},{"key":"e_1_3_4_140_1","unstructured":"Apogee therapeutics INC. Massachusetts 02453 (US). Methods of administering antibodies that bind interleukin 4 receptor alpha. WO2025166234A1. 2025."},{"key":"e_1_3_4_141_1","unstructured":"Yeda Research and Development Co. LTD. Rehovot (IL). Method of resolving dynamics of cellular transitions. WO2025134126A1. 2025."},{"key":"e_1_3_4_142_1","unstructured":"Codiak BioSciences INC. Cambridge MA (US). Sting agonist comprising exosomes for treating neuroimmunological disorders. US20230241089A1. 2023."},{"key":"e_1_3_4_143_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle-aso constructs targeting STAT6. US20230364127A1. 2023."},{"key":"e_1_3_4_144_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle-aso constructs targeting STAT6. WO2022076596A1. 2022."},{"key":"e_1_3_4_145_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle-aso constructs targeting STAT6. WO2021030776A1. 2021."},{"key":"e_1_3_4_146_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle-aso constructs targeting STAT6. WO2022076596A9. 2022."},{"key":"e_1_3_4_147_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle linked to a biologically active molecule via an optimized linker and anchoring moiety. WO2022178180A1. 2022."},{"key":"e_1_3_4_148_1","unstructured":"Codiak Biosciences INC. Cambridge MA (US). Extracellular vesicle compositions. WO2022212884A1. 2022."},{"key":"e_1_3_4_149_1","unstructured":"Lonza Sales AG Basel (CH). Extracellular vesicle linked to biologically active molecule via an optimized linker and an anchoring moiety. US20240189430A1. 2024."},{"key":"e_1_3_4_150_1","unstructured":"Lonza Sales AG Basel (CH). Extracellular vesicle compositions. US20240209368A1. 2024."},{"key":"e_1_3_4_151_1","unstructured":"Lonza Sales AG Basel (CH). Methods of loading extracellular vesicle US20250127919A1. 2025."},{"key":"e_1_3_4_152_1","unstructured":"The Board of Trustees of University of Illinois Urbana (US). Engineered exosomes for medical applications. WO2020023251A1. 2020."},{"key":"e_1_3_4_153_1","unstructured":"Lonza Sales AG Basel (CH). Extracellular vesicle comprising a biologically active molecule and a cleavable linker. WO2024040073A1. 2024."},{"key":"e_1_3_4_154_1","unstructured":"Lonza Sales AG Basel (CH). Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker. WO2024040075A1. 2024."},{"key":"e_1_3_4_155_1","unstructured":"Lonza Sales AG Basel (CH). Extracellular vesicle comprising a biologically active molecule and a cell penetrated peptide cleavable linker. WO2024040076A1. 2024."},{"key":"e_1_3_4_156_1","unstructured":"Lonza Sales AG Basel (CH). Methods of using extracellular vesicle-ASO targeting STAT6. WO2024118592A3. 2024."},{"key":"e_1_3_4_157_1","unstructured":"Mirae Nedim Ince Iowa Cxity [A (US); David Elliott lowa City IA (US). Active donor T cell STAT6. US20240189356A1. 2024."},{"key":"e_1_3_4_158_1","unstructured":"Unichem Laboratories LTD Maharashtra (IN). Anticancer proteins. US20230348564A1. 2023."},{"key":"e_1_3_4_159_1","unstructured":"Alnylam Pharmaceuticals INC. Cambridge MA (US). Signal transducer and activator of transcription factor 6 (STAT6) IRNA compositions and methods of use thereof. US20240254484A1. 2024."},{"key":"e_1_3_4_160_1","unstructured":"Alnylam Pharmaceuticals INC. Cambridge MA (US). Signal transducer and activator of transcription factor 6 (STAT6) IRNA compositions and methods of use thereof. WO2022232343A1. 2022."},{"key":"e_1_3_4_161_1","unstructured":"Twister Biotech LLC Houston TX 77225 (US) and Baylor College of Medicine Houston TX 77030 (US). Using minivectors to treat idiopathic pulmonary fibrosis. EP4338755A1. 2024."},{"key":"e_1_3_4_162_1","unstructured":"T\u014dwister Biotech INC. Houston TX (US); and Baylor College of Medicine Houston TX (US). Using minivectors to treat idiopathic pulmonary fibrosis. US20240100189A1. 2024."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2713551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2713551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2713551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:40:12Z","timestamp":1790865612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2713551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":160,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/13543776.2026.2713551"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2713551","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}